scholarly journals Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips

2018 ◽  
Vol Volume 11 ◽  
pp. 5777-5787 ◽  
Author(s):  
Qiang Tong ◽  
Xiao-long Wang ◽  
Sheng-bao Li ◽  
Gong-li Yang ◽  
Shu Jin ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Serum Markers ◽  
Esophageal Squamous Cell Cancer ◽  
Protein Chips ◽  
Preliminary Study ◽  
Combined Detection

Risk Patterns of Subsequent Primary Cancers following Esophagectomy in Early-Stage Thoracic Esophageal Squamous Cell Cancer Patients

2015 ◽  
Vol 101 (3) ◽  
pp. 328-333 ◽  
Author(s):  
Wen-Si Hu ◽  
Zeng-Jun Liu ◽  
Jian-Bo Zhang ◽  
Zeng-Liang Wang ◽  
Ning Yang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer

scholarly journals Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer

2021 ◽  
Author(s):  
Binhao Huang ◽  
Maria Christine Xu ◽  
Arjun Pennathur ◽  
Zhigang Li ◽  
Zhiguo Liu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Squamous Cell ◽  
Adjuvant Treatment ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
R0 Resection ◽  
Muscularis Mucosa

Abstract Objective To evaluate the outcome following the strategy of endoscopic R0 resection (ER) plus adjuvant treatment (AT) versus esophagectomy for esophageal squamous cell cancer in T1a invading muscularis mucosa (M3)-T1b stage. Methods We evaluated the outcomes of 46 esophageal squamous cell cancer (ESCC) patients with T1aM3-T1b stage who underwent ER + AT from the Esophageal Cancer Endoscopic Therapy Consortium (ECETC) and compared these outcomes to 92 patients who underwent esophagectomy. Propensity score matching (1:2) was used, with overall survival (OS) and relapse-free survival (RFS) being compared between the two groups. Results During a median follow-up of 32 months, there were no statistical differences (P = 0.226) in OS between the two groups. The 1-, 2-, and 3-year overall survival in the esophagectomy group was 95%, 91%, and 84%, respectively. There were no mortalities within three years in the ER + AT group. The RFS between the two groups was also not significantly different (P = 0.938). The 1-, 2-, and 3-year RFS of patients in the esophagectomy group was 90%, 90%, and 83%, respectively, while it was 97%, 94%, and 74% in the ER + AT group, respectively. The local recurrence rates between the two groups were not significantly different (P = 0.277). Conclusions This first multicenter analysis showed similar outcomes were found regarding OS and RFS between the two groups in T1aM3-T1b stage patients. ER + AT may be considered in high-risk patients or for those who refuse esophagectomy.

Total Care for Oral Tracheal and Esophageal Squamous Cell Cancer Employing Transnasal Esophagogastroduodenoscopy

2014 ◽  
Vol 65 (2) ◽  
pp. 113-114
Author(s):  
K. Kawada ◽  
Y. Nakajima ◽  
T. Kawano
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Total Care

Topical oro-dispersible budesonide tablets for stricture prevention after near circumferential ESD for esophageal squamous cell cancer – a case report

2021 ◽  
Author(s):  
Daniel Mathies ◽  
Tsuneo Oyama ◽  
Ingo Steinbrück ◽  
Franz Ludwig Dumoulin
Keyword(s):  
Case Report ◽  
High Risk ◽  
Endoscopic Resection ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Complete Healing ◽  
Esophageal Squamous Cell Cancer ◽  
Stricture Formation ◽  
Local Injections

Abstract Background Endoscopic resection is the treatment of choice for early esophageal cancers. However, resections comprising more than 70–80 % of the circumference are associated with a high risk of stricture formation. Currently, repetitive local injections and/or systemic steroids are given for prevention. Case report We present here the case of a 78-year-old male patient who had a near circumferential endoscopic submucosal dissection for a pT1a mm, L0, V0, R0, G2 esophageal squamous cell cancer. At the end of endoscopic resection, 80 mg of triamcinolone was injected locally. The patient was then treated with oro-dispersible budesonide tablets (2 × 1 mg/day) and nystatin (4 × 100 000 I.E.) for 8 weeks. This treatment resulted in complete healing without any stricture formation and did not result in any complications. Discussion Treatment with orodispersible budesonide tablets could help prevent strictures after large endoscopic resections in the esophagus.

scholarly journals Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yu-Chieh Ho ◽  
Yuan-Chun Lai ◽  
Hsuan-Yu Lin ◽  
Ming-Hui Ko ◽  
Sheng-Hung Wang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Performance Status ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Lymphocyte Ratio ◽  
Cardiac Dose

AbstractWe aimed to determine the prognostic significance of cardiac dose and hematological immunity parameters in esophageal cancer patients after concurrent chemoradiotherapy (CCRT). During 2010–2015, we identified 101 newly diagnosed esophageal squamous cell cancer patients who had completed definitive CCRT. Patients' clinical, dosimetric, and hematological data, including absolute neutrophil count, absolute lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR), at baseline, during, and post-CCRT were analyzed. Cox proportional hazards were calculated to identify potential risk factors for overall survival (OS). Median OS was 13 months (95% confidence interval [CI]: 10.38–15.63). Univariate analysis revealed that male sex, poor performance status, advanced nodal stage, higher percentage of heart receiving 10 Gy (heart V10), and higher NLR (baseline and follow-up) were significantly associated with worse OS. In multivariate analysis, performance status (ECOG 0 & 1 vs. 2; hazard ratio [HR] 3.12, 95% CI 1.30–7.48), heart V10 (> 84% vs. ≤ 84%; HR 2.24, 95% CI 1.26–3.95), baseline NLR (> 3.56 vs. ≤ 3.56; HR 2.36, 95% CI 1.39–4.00), and follow-up NLR (> 7.4 vs. ≤ 7.4; HR 1.95, 95% CI 1.12–3.41) correlated with worse OS. Volume of low cardiac dose and NLR (baseline and follow-up) were associated with worse patient survival.

Randomized, Placebo-Controlled, Esophageal Squamous Cell Cancer Chemoprevention Trial of Selenomethionine and Celecoxib

2005 ◽  
Vol 129 (3) ◽  
pp. 863-873 ◽  
Author(s):  
Paul J. Limburg ◽  
Wenqiang Wei ◽  
Dennis J. Ahnen ◽  
Youlin Qiao ◽  
Ernest T. Hawk ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Cancer Chemoprevention ◽  
Esophageal Squamous Cell Cancer ◽  
Chemoprevention Trial

scholarly journals GINS2 is Overexpressed in Esophageal Squamous Cell Cancer and Indicates Poor Survival Outcome

2017 ◽  
Vol 99 (2) ◽  
pp. E207-E208
Author(s):  
Y. Zhou ◽  
X. Liu ◽  
J. Li ◽  
N. Liu ◽  
Y. Dong ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Survival Outcome ◽  
Esophageal Squamous Cell Cancer ◽  
Poor Survival ◽  
Poor Survival Outcome
Sign in / Sign up

Export Citation Format

Share Document